West Virginia Medicaid Drug Utilization Review Board Minutes

MAY 26, 2021

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

K.C. Lovin, PA-C, Chair
Christopher Terpening, PharmD, PhD, Vice Chair
C.K. Babcock, PharmD
Michael Ballow, PharmD
Chris Booth, PharmD
Scott Brown, RPh
Myra Chiang, MD
Kate Forman, PharmD
Phillip Galapon, MD
David Gloss, MD
Lester Labus, MD
Michael Lonsinger, PharmD
Ernest Miller, DO
Mary Nemeth-Pyles, MSN, RN, CS

Members Absent:

none

DHHR/BMS Staff:

Brian Thompson, MS, PharmD, Director of Pharmacy Services Priya Shah, PharmD, Drug Utilization Review Coordinator Lori Moles, RPh, Staff Pharmacist Doug Sorvig, Analyst Gail Goodnight, Rebate Manager

Contract Staff:

Angie Wowczuk, PharmD, Rational Drug Therapy Program (RDTP) Kim Broedel-Zaugg, RPh, PhD, Marshall University Jon Willis, Marshall University Eric Sears, RPh, Gainwell Jacqueline Hedlund, MD, Change Healthcare Ryan Fell, PharmD, Change Healthcare

I. INTRODUCTIONS

a. K.C. Lovin, Chair, welcomed everyone to the Board meeting at 4:05pm EDT. The DUR Board introduced themselves.

II. ARRPOVAL OF MINUTES FROM February 24, 2021 DUR BOARD MEETING

a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

III. OLD BUSINESS

none

IV. NEW BUSINESS

- a. Speakers
 - i. none

b. Updates from April 28, 2021 P & T Committee Meeting

- i. Ryan Fell presented the updates from the April 28, 2021 P & T meeting for board review.
- c. Prior Authorization Criteria. Attachment A
 - i. Toujeo: approved as amended
 - ii. Dojolvi: approved as presented
 - iii. Omnipod: approved as amended
 - iv. Fintepla: approved as presented
 - v. <u>Xywav/xyrem:</u> approved as presented
 - vi. Emflaza: approved as presented
 - vii. Multiple Scherosis Agents: approved as presented
 - viii. Amondys 45: approved as presented
 - ix. Verguvo: approved as amended
 - x. <u>Lupknis and Benlysta:</u> approved as presented
 - xi. Oxlumo: approved as presented
 - xii. Analgesics, narcotic long acting: approved as presented

V. REPORTS – 1st Quarter 2021

- **a. Gainwell Technologies Quarterly Report:** Mr. Sears presented an overview of the 2021 First Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- **b.** Rational Drug Therapy Program: Dr. Wowczuk presented a review of the prior authorization program for the First Quarter of 2021. Attachment C
- c. **Marshall University Coalition:** Dr. Broedel-Zaugg reported on the progress of retro DUR, the lock in program, number of letters sent/returned, and quarterly newsletter. Attachment D

VI. OTHER BUSINESS

a. THANK YOU, Dr. Myra Chiang for your services to WV DUR! Best wishes!

VII. NEXT MEETING AND ADJOURNMENT

- **a.** The meeting concluded at 5:50 pm EDT.
- **b.** The next meeting will be September 22, 2021 from 4:00pm to 6:00pm virtually.